- 专利标题： REDUCING IMMUNOGENICITY TO PEGLOTICASE
-
申请号： US18376677申请日： 2023-10-04
-
公开(公告)号： US20240033331A1公开(公告)日： 2024-02-01
- 发明人: Jeffrey D. KENT , Brian LAMOREAUX
- 申请人： Horizon Therapeutics USA, Inc.
- 申请人地址： US IL Deerfield
- 专利权人： Horizon Therapeutics USA, Inc.
- 当前专利权人： Horizon Therapeutics USA, Inc.
- 当前专利权人地址： US IL Deerfield
- 主分类号： A61K38/44
- IPC分类号： A61K38/44 ; A61K31/5377 ; A61P19/06 ; A61K47/60 ; A61K9/00 ; A61K31/365
摘要：
The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and MMF. Also provided are methods of reducing intolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MMF.
信息查询
IPC分类:
